Literature DB >> 25022579

Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.

David J Farrell1, Rodrigo E Mendes2, Paul R Rhomberg2, Ronald N Jones2.   

Abstract

The reference broth microdilution (BMD) antimicrobial susceptibility testing method for telavancin was revised to include dimethyl sulfoxide (DMSO) as a solvent and diluent for frozen-form panel preparation, following the CLSI recommendations for water-insoluble agents. Polysorbate 80 (P-80) was also added to the test medium to minimize proven drug losses associated with binding to plastic surfaces. Four hundred sixty-two Gram-positive isolates, including a challenge set of organisms with reduced susceptibilities to comparator agents, were selected and tested using the revised method for telavancin, and the MIC results were compared with those tested by the previously established method and several Sensititre dry-form BMD panel formulations. The revised method provided MIC results 2- to 8-fold lower than the previous method when tested against staphylococci and enterococci, resulting in MIC50 values of 0.03 to 0.06 μg/ml for staphylococci and 0.03 and 0.12 μg/ml for Enterococcus faecium and Enterococcus faecalis, respectively. Less-significant MIC decreases (1 to 2 log2 dilution steps) were observed when testing streptococci in broth supplemented with blood, which showed similar MIC50 values for both methods. However, Streptococcus pneumoniae had MIC50 results of 0.008 and 0.03 μg/ml when tested by the revised and previous methods, respectively. Highest essential agreement rates (≥94.0%) were noted for one candidate dry-form panel formulation compared to the revised test. The revised BMD method provides lower MIC results for telavancin, especially when tested against staphylococci and enterococci. This is secondary to the use of DMSO for panel production and the presence of P-80, which ensure the proper telavancin testing concentration and result in a more accurate MIC determination. Moreover, earlier studies where the previous method was applied underestimated the in vitro drug potency.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25022579      PMCID: PMC4135820          DOI: 10.1128/AAC.03172-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).

Authors:  Rodrigo E Mendes; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2011-11-10       Impact factor: 2.803

2.  Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors:  Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

3.  In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

Authors:  Deborah C Draghi; Bret M Benton; Kevin M Krause; Clyde Thornsberry; Chris Pillar; Daniel F Sahm
Journal:  J Antimicrob Chemother       Date:  2008-04-19       Impact factor: 5.790

4.  Surveillance of dalbavancin potency and spectrum in the United States (2012).

Authors:  Ronald N Jones; Robert K Flamm; Helio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2013-02-20       Impact factor: 2.803

5.  In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.

Authors:  David J Farrell; Kevin M Krause; Bret M Benton
Journal:  Diagn Microbiol Infect Dis       Date:  2011-03       Impact factor: 2.803

6.  Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).

Authors:  Rodrigo E Mendes; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2011-09       Impact factor: 2.803

7.  Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.

Authors:  Rodrigo E Mendes; Helio S Sader; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

8.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

9.  Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Authors:  Deborah C Draghi; Bret M Benton; Kevin M Krause; Clyde Thornsberry; Chris Pillar; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

10.  Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.

Authors:  James E Ross; Rodrigo E Mendes; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

View more
  18 in total

1.  Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Authors:  Kristen L Bunnell; Manjunath P Pai; Monica Sikka; Susan C Bleasdale; Eric Wenzler; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.

Authors:  Rodrigo E Mendes; Helio S Sader; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

3.  Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm.

Authors:  Daniel G Meeker; Karen E Beenken; Weston B Mills; Allister J Loughran; Horace J Spencer; William B Lynn; Mark S Smeltzer
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.

Authors:  Abrar K Thabit; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

5.  Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.

Authors:  Rodrigo E Mendes; David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

6.  Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.

Authors:  Wessam Abdelhady; Arnold S Bayer; Rachelle Gonzales; Liang Li; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.

Authors:  Laura M Koeth; Jeanna M DiFranco-Fisher; Sandra McCurdy
Journal:  J Vis Exp       Date:  2015-09-09       Impact factor: 1.355

9.  In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.

Authors:  R K Flamm; P R Rhomberg; H S Sader
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  Antibacterial Activity of a Promising Antibacterial Agent: 22-(4-(2-(4-Nitrophenyl-piperazin-1-yl)-acetyl)-piperazin-1-yl)-22-deoxypleuromutilin.

Authors:  Xiang-Yi Zuo; Hong Gao; Mei-Ling Gao; Zhen Jin; You-Zhi Tang
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.